J. Safra Sarasin Holding AG Sells 63,939 Shares of Zoetis Inc. (NYSE:ZTS)

by · The Cerbat Gem

J. Safra Sarasin Holding AG reduced its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 18.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 291,430 shares of the company’s stock after selling 63,939 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Zoetis were worth $47,483,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Callahan Advisors LLC boosted its holdings in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after purchasing an additional 6,221 shares during the period. CIBC Asset Management Inc raised its position in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares in the last quarter. Pensionfund Sabic boosted its stake in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the period. PFW Advisors LLC purchased a new position in Zoetis during the fourth quarter worth about $1,764,000. Finally, Schroder Investment Management Group increased its stake in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock worth $40,036,000 after acquiring an additional 6,169 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Activity

In other news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Up 1.3 %

Shares of Zoetis stock opened at $148.64 on Monday. The company’s 50 day moving average price is $160.04 and its 200-day moving average price is $169.66. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a market capitalization of $66.32 billion, a price-to-earnings ratio of 27.17, a P/E/G ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.35%. Zoetis’s dividend payout ratio is currently 36.56%.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Stifel Nicolaus cut their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Barclays raised their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Piper Sandler upped their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $214.40.

Get Our Latest Report on ZTS

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).